- Home
- YMT vs ESLA Comparison
YMT vs ESLA Comparison
Compare YMT & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YMT | ESLA |
|---|---|---|
| Founded | 2011 | 2021 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.4M | 60.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | YMT | ESLA |
|---|---|---|
| Price | $0.61 | $1.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 294.0K | 57.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.53 | $0.73 |
| 52 Week High | $2.40 | $3.15 |
Technical Indicators
Market Signals| Indicator | YMT | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 32.65 | 41.58 |
| Support Level | N/A | $1.02 |
| Resistance Level | $1.84 | $1.18 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 16.40 | 31.02 |
Price Performance
Historical ComparisonAbout YMT Yimutian Inc. American Depositary Shares
Yimutian Inc is the largest agricultural B2B platform in mainland China. It provide a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching, matching, to transaction facilitation and settlement. The company pride itself as the go-to platform for merchants by leveraging its inventive technology and industry know-how. Its platform had over 38 million merchants. It has also established approximately 12 offline stores in mainland China to trade agricultural products at cultivation and production sites with sellers and buyers.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.